Paroxysmal nocturnal hemoglobinuria

Novartis Reveals Sustained Efficacy and Safety of Fabhalta in Patients Switching from Anti-C5 Therapies for Paroxysmal Nocturnal Hemoglobinuria (PNH)

5 months ago talkbio0Tagged anti-C5, Avoidance, Blood Transfusion, Effectiveness, Fabhalta, Hemoglobin improvement, Iptacopan, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Safety, Switching therapies

Fabhalta (iptacopan), Paroxysmal Nocturnal Hemoglobinuria (PNH), Anti-C5 therapies, Efficacy and safety, Switching therapies, Hemoglobin improvement, Transfusion avoidance

Roche’s PiaSky Receives European Approval for Rare Blood Disorder Treatment

8 months ago talkbio0Tagged Approved, Crovalimab, European (ethnic group), Infrequent, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PiaSky, PNH, Roche (company)

Roche, PiaSky, Crovalimab, Paroxysmal Nocturnal Hemoglobinuria (PNH), Rare Blood Disorder, European Approval

FDA Approves Amgen’s Bkemv, First Interchangeable Biosimilar to Soliris for Rare Blood Disorders ###

11 months ago talkbio0Tagged Alexion, amgen, Approved, AstraZeneca, Atypical, Atypical Hemolytic Uremic Syndrome, Biosimilars, Bkemv, Hemolytic-Uremic Syndrome, Infrequent, interchangeable, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Soliris, United States Food and Drug Administration

Bkemv, Soliris, FDA approval, Interchangeable biosimilar, Rare blood disorders, Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Amgen, AstraZeneca, Alexion Pharmaceuticals

Amgen Secures FDA Approval for Bkemv, the First Interchangeable Biosimilar to Soliris for Rare Blood Disorders

11 months ago talkbio0Tagged amgen, Approved, Atypical, Atypical Hemolytic Uremic Syndrome, Biosimilars, Bkemv, Hematological Disease, Hemolytic-Uremic Syndrome, Infrequent, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Soliris, United States Food and Drug Administration

FDA approval, Amgen, Bkemv, Soliris, biosimilar, rare blood disorders, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS)

Alexion Expands Indications for Long-Acting C5 Complement Inhibitor Ultomiris in Rare Autoimmune Disorder NMOSD

1 year ago talkbio0Tagged Alexion, Annals, Approved, AstraZeneca Rare Disease, C5 complement inhibitor, CHAMPIER-NMOSD trial, generalised myasthenia gravis, gMG, long-acting, Marc Dunoyer, Neurology speciality, Neuromyelitis Optica, Paroxysmal nocturnal hemoglobinuria, Publications, ravulizumab-cwvz, Ultomiris, United States Food and Drug Administration

Ultomiris, ravulizumab-cwvz, C5 complement inhibitor, neuromyelitis optica spectrum disorder (NMOSD), FDA approval, long-acting, zero relapses, CHAMPIER-NMOSD trial, Annals of Neurology publication, Marc Dunoyer, AstraZeneca Rare Disease, Alexion, generalised myasthenia gravis (gMG), paroxysmal nocturnal haemoglobinuria (PNH).